Moleculin Biotech (MBRX) Expected to Announce Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) is expected to post its quarterly earnings results before the market opens on Friday, March 21st. Analysts expect Moleculin Biotech to post earnings of ($1.25) per share for the quarter.

Moleculin Biotech Stock Performance

Moleculin Biotech stock traded up $0.05 on Thursday, hitting $1.09. 450,901 shares of the stock traded hands, compared to its average volume of 1,396,512. The business’s fifty day simple moving average is $1.38 and its 200 day simple moving average is $2.04. Moleculin Biotech has a 1 year low of $0.40 and a 1 year high of $7.80.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MBRX shares. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a report on Monday, March 3rd. Maxim Group downgraded Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. Finally, StockNews.com assumed coverage on Moleculin Biotech in a research note on Thursday, March 13th. They set a “sell” rating for the company.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.